文献速递造血干细胞移植与细胞治疗

CRISPR/Cas9 删除人 T 细胞 MIR155HG 在异种模型中降低急性 GVHD 发生率与严重程度

CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model.
PubMed 文献 · Blood Adv · 2024-01-01

本研究利用 CRISPR/Cas9 在来自人供者的原代 T 细胞中删除 miR-155(MIR155HGΔexon3),获得稳定持久的 miR-155 表达下降。在异种急性 GVHD 模型中,接受 MIR155HGΔexon3 人 T 细胞的 NSG 小鼠较接受 miR-155 完整人 T 细胞的小鼠免于致死性急性 GVHD,且保留移植物抗白血病(GVL)反应并显著改善异种 GVL 模型生存。

要点

  • CRISPR/Cas9 删除人原代 T 细胞 MIR155HG 可稳定持久降低 miR-155 表达。
  • 异种急性 GVHD 模型中,MIR155HGΔexon3 人 T 细胞较 miR-155 完整 T 细胞提供免于致死性急性 GVHD 的保护。
  • MIR155HGΔexon3 人 T 细胞保留 GVL 反应并显著改善异种 GVL 模型生存。

核心结论

  • CRISPR/Cas9 介导删除原代人供者 T 细胞 MIR155HG 可生成免于致死性 GVHD 且维持强抗白血病反应的异基因供者 T 细胞。

研究设计与样本

  • 临床前研究:用 CRISPR/Cas9 基因组编辑删除来自人供者原代 T 细胞的 miR-155(MIR155HGΔexon3),并在异种急性 GVHD 模型与异种 GVL 模型中评估。

主要发现

  • NSG 小鼠接受 MIR155HGΔexon3 人 T 细胞较接受 miR-155 完整人 T 细胞免于致死性急性 GVHD。
  • MIR155HGΔexon3 人 T 细胞在受者体内持续存在,增殖潜能下降,致病性 T 辅助-1 细胞群体减少,并向肝脏和皮肤等 GVHD 靶器官浸润减少。
  • MIR155HGΔexon3 人 T 细胞保留 GVL 反应,在体内异种 GVL 模型中显著改善生存。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic cell transplantation (allo-HCT). Using preclinical mouse models of disease, previous work in our laboratory has linked microRNA-155 (miR-155) to the development of acute GVHD. Transplantation of donor T cells from miR-155 host gene (MIR155HG) knockout mice prevented acute GVHD in multiple murine models of disease while maintaining critical graft-versus-leukemia (GVL) response, necessary for relapse prevention. In this study, we used clustered, regularly interspaced, short palindromic repeats (CRISPR)/Cas9 genome editing to delete miR-155 in primary T cells (MIR155HGΔexon3) from human donors, resulting in stable and sustained reduction in expression of miR-155. Using the xenogeneic model of acute GVHD, we show that NOD/SCID/IL2rγnull (NSG) mice receiving MIR155HGΔexon3 human T cells provide protection from lethal acute GVHD compared with mice that received human T cells with intact miR-155. MIR155HGΔexon3 human T cells persist in the recipients displaying decreased proliferation potential, reduced pathogenic T helper-1 cell population, and infiltration into GVHD target organs, such as the liver and skin. Importantly, MIR155HGΔexon3 human T cells retain GVL response significantly improving survival in an in vivo model of xeno-GVL. Altogether, we show that CRISPR/Cas9-mediated deletion of MIR155HG in primary human donor T cells is an innovative approach to generate allogeneic donor T cells that provide protection from lethal GVHD while maintaining robust antileukemic response.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Neidemire-Colley L, Khanal S, Braunreiter KM, et al. CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model. Blood Adv. 2024. PMID: 38181781. doi:10.1182/bloodadvances.2023010570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。